Risk of non-melanoma skin cancer with biological therapy in common inflammatory diseases: a systemic review and meta-analysis

Abstract Background Most previous studies compared the risk for non-melanoma skin cancer (NMSC) in biologic-treated common inflammatory diseases with the general population. Whether the increased NMSC risk is caused by the disease itself, the biologics, or both remains unknown. Methods We systematic...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ruolin Liu, Qianyi Wan, Rui Zhao, Haitao Xiao, Ying Cen, Xuewen Xu
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Non-melanoma skin cancer Inflammatory bowel disease Psoriasis Rheumatoid arthritis Biologics Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Cytology QH573-671
Acceso en línea:	https://doaj.org/article/22b616d7155c448da005b4c2b2a7582e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:22b616d7155c448da005b4c2b2a7582e
record_format	dspace
spelling	oai:doaj.org-article:22b616d7155c448da005b4c2b2a7582e2021-11-28T12:36:51ZRisk of non-melanoma skin cancer with biological therapy in common inflammatory diseases: a systemic review and meta-analysis10.1186/s12935-021-02325-91475-2867https://doaj.org/article/22b616d7155c448da005b4c2b2a7582e2021-11-01T00:00:00Zhttps://doi.org/10.1186/s12935-021-02325-9https://doaj.org/toc/1475-2867Abstract Background Most previous studies compared the risk for non-melanoma skin cancer (NMSC) in biologic-treated common inflammatory diseases with the general population. Whether the increased NMSC risk is caused by the disease itself, the biologics, or both remains unknown. Methods We systematically searched PubMed, Embase, Medline, Web of Science, and Cochrane Library from inception to May 2021. Studies were included if they assessed the risk of NMSC for rheumatoid arthritis (RA), inflammatory bowel disease (IBD), or psoriasis patients treated with biologics compared with patients not receiving biologics. Pooled relative risks (RRs) and 95% confidence intervals (CIs) were calculated using the fixed- or random-effects model. Results The current meta-analysis included 12 studies. Compared with patients with the inflammatory disease without biologics, patients receiving biological therapy were associated with an increased risk for NMSC (RR 1.25, 95% CI 1.14 to 1.37), especially in patients with RA (RR 1.24, 95% CI 1.13 to 1.36) and psoriasis (RR 1.28, 95% CI 1.07 to 1.52), but not in patients with IBD (RR 1.49, 95% CI 0.46 to 4.91). The risks for squamous cell skin cancer and basal cell skin cancer were both increased for patients receiving biologics. However, the risk of NMSC did not increase in patients treated with biologics less than 2 years. Conclusions Current evidence suggests that increased risk of NMSC was identified in RA and psoriasis treated with biologics compared with patients not receiving biologics, but not in patients with IBD. The inner cause for the increased risk of NMSC in IBD patients should be further discussed.Ruolin LiuQianyi WanRui ZhaoHaitao XiaoYing CenXuewen XuBMCarticleNon-melanoma skin cancerInflammatory bowel diseasePsoriasisRheumatoid arthritisBiologicsNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282CytologyQH573-671ENCancer Cell International, Vol 21, Iss 1, Pp 1-17 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Non-melanoma skin cancer Inflammatory bowel disease Psoriasis Rheumatoid arthritis Biologics Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Cytology QH573-671
spellingShingle	Non-melanoma skin cancer Inflammatory bowel disease Psoriasis Rheumatoid arthritis Biologics Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Cytology QH573-671 Ruolin Liu Qianyi Wan Rui Zhao Haitao Xiao Ying Cen Xuewen Xu Risk of non-melanoma skin cancer with biological therapy in common inflammatory diseases: a systemic review and meta-analysis
description	Abstract Background Most previous studies compared the risk for non-melanoma skin cancer (NMSC) in biologic-treated common inflammatory diseases with the general population. Whether the increased NMSC risk is caused by the disease itself, the biologics, or both remains unknown. Methods We systematically searched PubMed, Embase, Medline, Web of Science, and Cochrane Library from inception to May 2021. Studies were included if they assessed the risk of NMSC for rheumatoid arthritis (RA), inflammatory bowel disease (IBD), or psoriasis patients treated with biologics compared with patients not receiving biologics. Pooled relative risks (RRs) and 95% confidence intervals (CIs) were calculated using the fixed- or random-effects model. Results The current meta-analysis included 12 studies. Compared with patients with the inflammatory disease without biologics, patients receiving biological therapy were associated with an increased risk for NMSC (RR 1.25, 95% CI 1.14 to 1.37), especially in patients with RA (RR 1.24, 95% CI 1.13 to 1.36) and psoriasis (RR 1.28, 95% CI 1.07 to 1.52), but not in patients with IBD (RR 1.49, 95% CI 0.46 to 4.91). The risks for squamous cell skin cancer and basal cell skin cancer were both increased for patients receiving biologics. However, the risk of NMSC did not increase in patients treated with biologics less than 2 years. Conclusions Current evidence suggests that increased risk of NMSC was identified in RA and psoriasis treated with biologics compared with patients not receiving biologics, but not in patients with IBD. The inner cause for the increased risk of NMSC in IBD patients should be further discussed.
format	article
author	Ruolin Liu Qianyi Wan Rui Zhao Haitao Xiao Ying Cen Xuewen Xu
author_facet	Ruolin Liu Qianyi Wan Rui Zhao Haitao Xiao Ying Cen Xuewen Xu
author_sort	Ruolin Liu
title	Risk of non-melanoma skin cancer with biological therapy in common inflammatory diseases: a systemic review and meta-analysis
title_short	Risk of non-melanoma skin cancer with biological therapy in common inflammatory diseases: a systemic review and meta-analysis
title_full	Risk of non-melanoma skin cancer with biological therapy in common inflammatory diseases: a systemic review and meta-analysis
title_fullStr	Risk of non-melanoma skin cancer with biological therapy in common inflammatory diseases: a systemic review and meta-analysis
title_full_unstemmed	Risk of non-melanoma skin cancer with biological therapy in common inflammatory diseases: a systemic review and meta-analysis
title_sort	risk of non-melanoma skin cancer with biological therapy in common inflammatory diseases: a systemic review and meta-analysis
publisher	BMC
publishDate	2021
url	https://doaj.org/article/22b616d7155c448da005b4c2b2a7582e
work_keys_str_mv	AT ruolinliu riskofnonmelanomaskincancerwithbiologicaltherapyincommoninflammatorydiseasesasystemicreviewandmetaanalysis AT qianyiwan riskofnonmelanomaskincancerwithbiologicaltherapyincommoninflammatorydiseasesasystemicreviewandmetaanalysis AT ruizhao riskofnonmelanomaskincancerwithbiologicaltherapyincommoninflammatorydiseasesasystemicreviewandmetaanalysis AT haitaoxiao riskofnonmelanomaskincancerwithbiologicaltherapyincommoninflammatorydiseasesasystemicreviewandmetaanalysis AT yingcen riskofnonmelanomaskincancerwithbiologicaltherapyincommoninflammatorydiseasesasystemicreviewandmetaanalysis AT xuewenxu riskofnonmelanomaskincancerwithbiologicaltherapyincommoninflammatorydiseasesasystemicreviewandmetaanalysis
_version_	1718407879611908096

Risk of non-melanoma skin cancer with biological therapy in common inflammatory diseases: a systemic review and meta-analysis

Ejemplares similares